Akhter Mohammad S, Uddin Mohammad A, Schally Andrew V, Kubra Khadeja-Tul, Barabutis Nektarios
School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, 1800 Bienville Drive, Monroe, LA, 71201, USA.
Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, Miami, FL, USA.
J Cell Commun Signal. 2021 Mar;15(1):125-129. doi: 10.1007/s12079-020-00593-0. Epub 2020 Nov 13.
Growth hormone releasing hormone (GHRH) antagonists enhance endothelial barrier function and counteract the LPS-induced lung endothelial hyperpermeability, the cardinal feature of the acute respiratory distress syndrome (ARDS). The unfolded protein response (UPR) is a multifaceted molecular mechanism, strongly involved in tissue defense against injury. The current study introduces the induction of UPR by GHRH antagonists, since those peptides induced several UPR activation markers, including the inositol-requiring enzyme-1α (IRE1α), the protein kinase RNA-like ER kinase (PERK), and the activating transcription factor 6 (ATF6). On the other hand, the GHRH agonist MR-409 exerted the opposite effects. Furthermore, GHRH antagonists counteracted the kifunensine (UPR suppressor)-induced lung endothelial barrier dysfunction. Our observations suggest that UPR mediates, at least in part, the protective effects of GHRH antagonists in the lung microvasculature. To the best of our knowledge; this is the first study to provide experimental evidence in support of the hypothesis that UPR induction is a novel mechanism by which GHRH antagonists oppose severe human disease, including ARDS.
生长激素释放激素(GHRH)拮抗剂可增强内皮屏障功能,并对抗脂多糖诱导的肺内皮细胞高通透性,这是急性呼吸窘迫综合征(ARDS)的主要特征。未折叠蛋白反应(UPR)是一种多方面的分子机制,在组织防御损伤中发挥重要作用。本研究介绍了GHRH拮抗剂对UPR的诱导作用,因为这些肽诱导了几种UPR激活标志物,包括肌醇需要酶-1α(IRE1α)、蛋白激酶RNA样内质网激酶(PERK)和激活转录因子6(ATF6)。另一方面,GHRH激动剂MR-409则产生相反的效果。此外,GHRH拮抗剂可对抗 kifunensine(UPR抑制剂)诱导的肺内皮屏障功能障碍。我们的观察结果表明,UPR至少部分介导了GHRH拮抗剂在肺微血管中的保护作用。据我们所知,这是第一项提供实验证据支持UPR诱导是GHRH拮抗剂对抗包括ARDS在内的严重人类疾病的新机制这一假设的研究。